Global Exosome Trials

Erscheinungsjahr 2026
ISBN: 978-3-031-96419-0
Verlag: Springer

Buch, Englisch, 375 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 815 g

This book offers a comprehensive review of the global exosome trials that are registered with the United States National Institutes of Health website, clinicaltrials.gov. Clinicaltrials.gov is the largest listing of research studies in the world. The study titles are provided, as is the country of origin and the Clinical Trial Number in order to make it easier for the reader to locate the study and obtain further information. The book begins with an introduction to exosomes and exosome therapy, which involves the injection or infusion of exosomes, making it less invasive than traditional gene therapy, which involves the introduction, removal, or alteration of genetic material. Subsequent chapters discuss exosome therapy trials in many disciplines. The book covers topics such as Alzheimer's disease, back pain, cancer, dementia, neuralgia, diabetic retinopathy, and others. Chapters will examine currently recruiting studies as well as soon-to-be recruiting studies. 

 will be a valuable resource for neurologists, neurosurgeons, ophthalmologists, related and allied physicians, PhDs, and researchers. 

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Weiss, Jeffrey N.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Augenheilkunde, Optometrie

Inhaltsverzeichnis

Section 1. Introduction.- Chapter 1. What are Exosomes?- Chapter 2. Tables.- Section 2: Neurologic Exosome Therapy Trials.- Chapter 3. Alzheimer's Disease.- Chapter 4. Back Pain.- Chapter 5. Cancer.- Chapter 6. Depression, Anxiety, and Dementia.- Chapter 7. Epilepsy.- Chapter 8. Knee Pain.- Chapter 9. Low Birth Weight Infants.- Chapter 10. Meningitis.- Chapter 11. Myasthenia Gravis.- Chapter 12. Neuralgia.- Chapter 13. Parkinson's Disease.- Chapter 12. Sleep Apnea.- Chapter 13. Stroke.- Section 3: Ophthalmic Exosome Therapy Trials.- Chapter 14. Dry Eyes.- Chapter 15. Diabetic Retinopathy.- Chapter 16. Macular Hole.- Chapter 17. Retinitis Pigmentosa.

Über Autor(innen)

Jeffrey N. Weiss, M.D., is the former Chief of Retinal Surgery at the Joslin Diabetes Center in Boston, Faculty of Harvard Medical School, and Visiting Scientist at the Massachusetts Institute of Technology.

Dr. Weiss is the author of more than 100 publications, including 30 books, holds more than 23 U.S. and foreign patents and has been a Reviewer for multiple scholarly journals.  He has served as a Visiting Professor, performed surgery, and lectured both nationally and internationally.  Dr. Weiss is also the founder of two companies, Ocular Research Associates Inc., and Micron Ophthalmic, Inc., which have manufactured and sold Dr. Weiss’ inventions worldwide.

Dr. Weiss was the first to invent the equipment and develop the technique to safely perform retinal vessel cannulation. This surgery remains the only option for patients with severe stroke in the eye. He was also the first to report the use of hyperbaric oxygen treatment to successfully treat dry age-related macular degeneration and longer standing central retinal artery occlusions.

Dr. Weiss performed the first retinal stem cell surgery in 2010, and is the Principal Investigator of The Stem Cell Ophthalmology Treatment Studies I/II, the largest retinal and optic nerve stem cell studies in the world, and The Neurologic Stem Cell Treatment Study. The studies are Institutional Review Board (IRB) approved, registered with NIH, and listed on ClinicalTrials.gov